Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma have?
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma has 369 citations in the OpenAlex counts ScholarIQ stores.
When was Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma published?
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma has 2014 year in the ScholarIQ index.
What is the open-access status of Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma?
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma has hybrid oa status in the ScholarIQ index.
What is the DOI of Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma?
The DOI for Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma is on the source record.
What is the PMID of Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma?
The PMID for Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma is on the source record.
What is the OpenAlex record for Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma?
The OpenAlex for Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma is on the source record.